At a glance
ClinicalIndex Comparison RecordN/ACompleted· 1,031 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Screening of Colorectal Cancer Using Improved SEPT9 (Septin 9) Gene Methylation Assay in Chinese Population
BioChain (Beijing) Science and Technology, Inc.·observational·Posted Sep 4, 2015·Updated Jan 11, 2016
In Brief
An observational study for Colorectal Cancer and 4 related conditions. Completed, enrolled 1,031 participants across 4 sites.
Detailed Summary
The purpose of this study is to evaluate the performance of the SEPT9 gene methylation assay in Colorectal cancer (CRC) high-risk population in Chinese hospitals using the opportunistic screening method. The trial plans to evaluate a Chinese domestic SEPT9 assay kit produced by BioChain (Beijing) Science and Technology Corporation, who is a close partner of Epigenomics AG, the producer for Epi proColon 2.0 CE.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsColorectal Cancer, Adenomatous Polyp of Colon, Polyps, Other Disease/Injury, Other Cancers
CountriesChina
Timeline
N/ACompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartFeb 2014
Primary CompletionSep 2015
First PostedSep 2015
Study CompletionOct 2015
TodayJul 2026
First PostedSep 4, 2015
Enrollment StartFeb 1, 2014
Primary CompletionSep 1, 2015
Study CompletionOct 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 10.8 years ago